References
- Martinez‐Taboada V. M., Val‐Bernal J. F., Pesquera L. C., Fernandez‐Llanio N. E., Esteban J. M. P., Blanco R., et al. Demyelinating disease and cutaneous lymphocitic vasculitis after etanercept therapy in a patient with rheumatoid arthritis. Scand J Rheumatol 2006; 35: 322–3
- The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo‐controlled multicenter study. Neurology 1999; 53: 457–65
- Schwid S. R., Noseworthy J. H. Targeting immunotherapy in multiple sclerosis: a near hit and a clear miss. Neurology 1999; 53: 444–5
- van Oosten B. W., Barkhof F., Truyen L., Boringa J. B., Bertelsmann F. W., von Blomberg B. M. E., et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti‐tumor necrosis factor antibody cA2. Neurology 1996; 47: 1531–4